Background {#Sec1}
==========

Both rheumatoid factor (RF) and anticyclic citrullinated peptide antibodies (anti-CCP) are useful for diagnosing rheumatoid arthritis (RA) \[[@CR1], [@CR2]\], and they have been shown to be associated with the progression of joint destruction in patients with RA \[[@CR3], [@CR4]\]. However, the influence of these autoantibodies on the clinical status and disease activity of patients with RA has yet to be fully clarified.

RF and anti-CCP have recently been shown to influence the efficacy of some non-tumor necrosis factor (non-TNF) biological disease-modifying antirheumatic drugs (DMARDs) \[[@CR5]--[@CR9]\]. However, the influence of these autoantibodies on the efficacy of TNF inhibitors, the first biological DMARDs approved for RA, has been controversial \[[@CR10]--[@CR16]\].

The RISING study was a randomized, double-blind trial that demonstrated the usefulness of dose escalation of infliximab (IFX) in RA \[[@CR17]\]. In a post hoc analysis of this study, we previously reported that the baseline plasma TNF level greatly influenced serum IFX levels and predicted clinical response at 1 year \[[@CR18]\].

RF/anti-CCP double-positive but not single-positive patients with RA were reported to show significantly higher circulating TNF levels than double-negative patients \[[@CR19]\]. We therefore hypothesized that "both RF-high and anti-CCP-high" would correlate with a higher TNF level, which would result in a lower IFX level and clinical response. In the present analysis using data from the RISING study, we explored the association between baseline RF and anti-CCP titers with efficacy of IFX therapy in patients with active RA despite methotrexate (MTX) treatment.

Methods {#Sec2}
=======

Study protocol {#Sec3}
--------------

The protocol of the RISING study has been published elsewhere \[[@CR17], [@CR18]\]. Patients with active RA (diagnosed according to 1987 American College of Rheumatology criteria \[[@CR20]\]) despite MTX treatment were treated with a standard dose (3 mg/kg) of an IFX originator (Remicade; Mitsubishi Tanabe Pharma Corporation, Osaka, Japan) at weeks 0, 2, and 6 (W0, W2, and W6, respectively), after which they were randomized to three dosing groups and treated with 3, 6, or 10 mg/kg of IFX every 8 weeks from W14 to W46. Active RA was defined by the presence of at least six swollen joints, at least six tender joints, and an erythrocyte sedimentation rate ≥ 28 mm/h or a serum C-reactive protein (CRP) level ≥ 2.0 mg/dl.

Disease activity and laboratory testing {#Sec4}
---------------------------------------

Disease activity was evaluated by the Disease Activity Score in 28 joints based on C-reactive protein (DAS28-CRP). Because there is controversy about the cutoff level of DAS28-CRP, which might underestimate disease activity when using cutoff values validated for DAS28 based on erythrocyte sedimentation rate \[[@CR21]\], we used the cutoff levels that were previously estimated in Japanese patients with RA as follows: clinical remission (REM) \< 2.3, low disease activity without clinical remission (LDA), ≥ 2.3 but \< 2.7, moderate disease activity (MDA) ≥ 2.7 but ≤ 4.1, and high disease activity (HDA) \> 4.1 \[[@CR22]\].

RF titers were measured by a latex agglutination test using the Auto LIA-RF kit (Nissui Pharmaceutical Co., Tokyo, Japan) with a detectable limit of ≥ 3 IU/ml (normal range ≤ 15 IU/ml). Anti-CCP titers were measured by performing an enzyme-linked immunosorbent assay (ELISA) using the DIASTAT anti-CCP kit (Euro Diagnostica, Malmö, Sweden) with a detectable range of ≥ 0.6 to \< 100 U/ml (normal range ≤ 5.0 U/ml). Disease activity, RF, and anti-CCP at W54 were evaluated using the last observation carried forward approach.

Baseline plasma TNF levels (just before the first IFX infusion) were measured by ELISA using the QuantiGlo ELISA Kit (QTA00B; R&D Systems Inc., Minneapolis, MN, USA) as described previously \[[@CR18]\]. Baseline plasma interleukin (IL)-6 and serum matrix metalloproteinase (MMP)-3 levels were measured by ELISA \[[@CR18]\]. All laboratory tests were performed at LSI Medience Corporation (Tokyo, Japan).

Serum IFX levels and anti-infliximab antibody (ATI) positivity were measured by ELISA \[[@CR17]\] at Mitsubishi Tanabe Pharma Corporation using the same ELISA system (Janssen Biotech, Inc.; Horsham, PA, USA) as that used in previous phases II and III studies for RA \[[@CR23]--[@CR25]\]. IFX levels were evaluated at W2, W6, W10, W14, and W54, with the lower detection level of \< 0.1 μg/ml. ATI positivity was evaluated at W54 in study completers or at 12 weeks after the last infusion in noncompleters. Patients with detectable serum IFX levels were considered to be ATI-negative and were not evaluated for ATI positivity (i.e., serum IFX levels were \< 0.1 μg/ml in all ATI-positive patients), as described previously \[[@CR17], [@CR23]--[@CR25]\].

Stratification of patients using baseline RF and anti-CCP titers {#Sec5}
----------------------------------------------------------------

Baseline RF and anti-CCP cutoff values for patient stratification were defined as follows: RF-low \< 55 IU/ml and RF-high ≥ 160 IU/ml (both are tertile values at baseline in this study) and anti-CCP-low \< 42 U/ml and anti-CCP-high ≥ 100 U/ml. The lower cutoff for anti-CCP of 42 U/ml was the first tertile for baseline anti-CCP titer, whereas the upper cutoff of 100 U/ml corresponded to the upper detection limit for anti-CCP (Additional file [1](#MOESM1){ref-type="media"}).

Patients with RA were then stratified into the following three classes on the basis of the above-mentioned cutoff values: low/low class (both RF-low and anti-CCP-low, low/low-C), high/high class (both RF-high and anti-CCP-high, high/high-C), and middle class (patients who did not meet the criteria for either class, middle-C) (Additional file [2](#MOESM2){ref-type="media"}). The following data were compared between the three classes: baseline plasma TNF level, serum IFX levels at W2, W6, W10, W14, and W54, and disease activities at W0, W2, W6, W10, W14, and W54.

Statistical analysis {#Sec6}
--------------------

Spearman's rank correlation test was used to evaluate the correlation of baseline RF titer and baseline anti-CCP titer with patient characteristics, serum IFX levels, and disease activity. The Kruskal-Wallis test or chi-square test was used to compare patients' characteristics, IFX levels, and disease activity among the three dosing groups (3, 6, and 10 mg/kg) or among three classes stratified on the basis of RF/anti-CCP at baseline (low/low-C, middle-C, and high/high-C). In addition, RF titers, anti-CCP titers, and the rate of three classes at W30 and W54 were compared with those at baseline (W0) using the Wilcoxon signed-rank test in each dosing group. All statistical analyses were performed using SAS version 9.4 software (SAS Institute Japan Ltd., Tokyo, Japan). *p* \< 0.05 (two-tailed) was considered to indicate statistical significance.

Results {#Sec7}
=======

Patient baseline characteristics and clinical response at week 54 {#Sec8}
-----------------------------------------------------------------

Table [1](#Tab1){ref-type="table"} shows patient baseline characteristics and clinical response at W54 for each IFX dosing group. Median (IQR), first tertile, and second tertile of baseline RF titers were 92 (37--237), 55, and 160 IU/ml, respectively (Additional file [1](#MOESM1){ref-type="media"}). The proportion of patients who were RF-negative (≤15 IU/ml) was 13% (41 of 307). Although no significant difference was observed in patient baseline characteristics among three dosing groups, the RF-negative rate tended to be high in the 3 mg/kg group.Table 1Characteristics of patients at baseline and clinical response at week 54 in each dosing group3 mg/kg6 mg/kg10 mg/kg*p* ValueAt baseline (week 0)(*n* = 99)(*n* = 104)(*n* = 104) Age, years49.7 (11.7)48.8 (11.8)50.4 (12.5)0.5370 Female sex78 (79%)86 (83%)89 (86%)0.4446^a^ Disease duration, years8.3 (7.8)7.2 (7.1)8.4 (7.7)0.4114 MTX dose, mg/week7.8 (1.6)7.9 (1.9)7.7 (1.7)0.6510 DAS28-CRP5.59 (4.89, 6.31)5.38 (4.85, 6.36)5.50 (5.10, 6.11)0.8026 TNF, pg/ml0.92 (\< 0.55, 1.29)0.97 (0.70, 1.31)0.89 (\< 0.55, 1.24)0.1320 RF  Median (IQR), IU/ml128 (27, 280)82 (37, 273)89 (43, 187)0.6361  Range (minimum, maximum), IU/ml\< 3, 1700\< 3, 2340\< 3, 1950  Negative (≤ 15 IU/ml)19 (19%)14 (13%)8 (8%)0.0551^a^ Anti-CCP  Median (interquartile range), U/ml≥ 100 (26, ≥ 100)≥ 100 (23, ≥ 100)≥ 100 (37, ≥ 100)0.1308  Range (minimum, maximum), U/ml\< 0.6, ≥ 100\< 0.6, ≥ 100\< 0.6, ≥ 100  Negative (≤ 5.0 U/ml)9 (9%)12 (12%)4 (4%)0.1171^a^At week 54(*n* = 99)(*n* = 104)(*n* = 104) DAS28-CRP at week 543.02 (2.13, 4.25)2.72 (1.59, 3.99)2.52 (1.69, 3.65)0.0394  REM/LDA/MDA/HDA30 (30%)/11 (11%)/27 (27%)/31 (31%)41 (39%)/10 (10%)/29 (28%)/24 (23%)47 (45%)/9 (9%)/31 (30%)/17 (16%)0.0384 RF, IU/ml61 (6, 152)38 (8, 91)42 (9, 76)0.3386 Anti-CCP, U/ml≥ 100 (12, ≥ 100)47 (12, ≥ 100)≥ 100 (24, ≥ 100)0.1079*Abbreviations: CCP*, Cyclic citrullinated peptide antibodies, *DAS28-CRP* Disease Activity Score in 28 joints based on C-reactive protein, *HDA* high disease activity, *LDA* Low disease activity without clinical remission, *MDA* Moderate disease activity, *MTX* Methotrexate, *REM* Clinical remission, *RF* Rheumatoid factor, *TNF* Tumor necrosis factorData are mean (SD), median (interquartile range), or number (%), unless otherwise described. The Kruskal-Wallis test was used to evaluate the differences among three dosing groups, except where indicated otherwise. Disease activity, RF, and anti-CCP at Week 54 were evaluated using the last observation carried forward approach. Cutoff values for DAS28-CRP were as follows: REM, \<2.3; LDA, ≥2.3-- \< 2.7; MDA, ≥2.7-- ≤ 4.1; HDA, \> 4.1 \[[@CR22]\]^a^Chi-square test was used to evaluate the differences among three dosing-groups

The median (IQR) and first tertile of baseline anti-CCP titers were ≥ 100 (28, ≥ 100) and 42 U/ml, respectively. The proportion of patients with a baseline anti-CCP titer above the upper detection limit (≥ 100 U/ml) was 58% (177 of 307), and the proportion of patients who were anti-CCP-negative (≤ 5.0 U/ml) was 8% (25 of 307). The proportion of patients who were seronegative for both RF and anti-CCP was 6% (19 of 307). Comorbidity was observed in 78% of patients; the major comorbidities were hypertension (21%), pollinosis (17%), osteoporosis (13%), and anemia (12%).

Table [1](#Tab1){ref-type="table"} also shows the clinical responses of the 3, 6, and 10 mg/kg dosing groups at W54. Significant differences in DAS28-CRP and disease activity criteria at W54 were observed among the three dosing groups. In contrast, both RF and anti-CCP titers significantly decreased after IFX treatment in each dosing group; however, no significant difference was observed among the three dosing groups (Additional file [3](#MOESM3){ref-type="media"}).

Correlations of baseline RF and anti-CCP titers with patient baseline characteristics {#Sec9}
-------------------------------------------------------------------------------------

Table [2](#Tab2){ref-type="table"} shows the correlations of baseline RF and anti-CCP titers with patient baseline characteristics. The baseline RF titer showed significant correlations with sex, age, duration of disease, total modified Sharp score, MMP-3, and anti-CCP, as well as TNF level, although the correlation coefficient for each was low. In contrast, the baseline anti-CCP titer showed significant correlations with comorbidity and RF as well as TNF level. Accordingly, TNF level was the only baseline characteristic that correlated with both RF and anti-CCP.Table 2Correlation of rheumatoid factor and anti-cyclic citrullinated peptide antibodies with patient characteristics at baseline (week 0)RF at week 0Anti-CCP at week 0Rho*p* ValueRho*p* ValueSex (0 = male, 1 = female)−0.1570.0057−0.0430.4489Age0.1540.00700.1060.0643BMI0.0370.51410.0160.7863Disease duration0.1190.0368−0.0460.4225NSAID use^a^−0.0060.91190.0220.7021Glucocorticoid use^a^0.0220.69670.0230.6893DMARD (other than MTX) use^a^−0.0510.37270.0650.2549Duration of MTX use0.0500.38320.0090.8687MTX dose−0.0690.2256−0.0130.8184Comorbidity^a^−0.0230.68740.1290.0240DAS28-CRP0.0870.12780.0420.4596Total modified Sharp score0.1320.0214−0.0190.7385HAQ0.0890.11860.0810.1557MMP-3−0.1290.0236−0.0570.3198IL-60.0690.22870.0400.4809TNF0.2090.00020.1170.0413RF----0.373\<0.0001Anti-CCP0.373\<0.0001----*Abbreviations: BMI* Body mass index, *CCP* Cyclic citrullinated peptide antibodies, *DAS28-CRP* Disease Activity Score in 28 joints based on C-reactive protein, *HAQ* Health Assessment Questionnaire, *IL-6* Interleukin-6, *MMP-3* Matrix metalloproteinase-3, *MTX* Methotrexate, NSAID Nonsteroidal anti-inflammatory drug, *RF* Rheumatoid factor, *Rho* Spearman's rank correlation coefficient, *TNF* Tumor necrosis factor^a^Categories of response are 0 = no, 1 = yes

Correlations of baseline RF and anti-CCP titers with serum IFX levels {#Sec10}
---------------------------------------------------------------------

We previously reported a significant negative correlation between the TNF level and IFX level \[[@CR18]\]. In the present analysis, we explored the association of baseline RF and anti-CCP titers with IFX levels in W2 to W14 in patients receiving 3 mg/kg of IFX (Table [3](#Tab3){ref-type="table"}). Similarly to our previous findings regarding TNF and IFX levels, significant negative correlations were noted between IFX levels and both baseline RF and anti-CCP titers at all time points (W2 to W14). Among the other patient baseline characteristics analyzed, only sex was significantly correlated with IFX levels at all time points.Table 3Correlation of rheumatoid factor and anti-cyclic citrullinated peptide antibodies at baseline with serum infliximab levelsSerum infliximab levelWeek 2Week 6Week 10Week 14Rho*p* ValueRho*p* ValueRho*p* ValueRho*p* ValueSex (0 = male, 1 = female)0.302\< 0.00010.2110.00020.1900.00080.1600.0049Age0.0040.93810.0640.26640.0300.59650.0040.9472BMI0.1600.00490.0540.34680.0330.5620−0.0150.7946Disease duration0.0980.08520.1120.04900.1060.06310.0930.1022NSAID use^a^−0.0870.1303−0.0180.7588−0.0390.4941−0.0600.2964Glucocorticoid use^a^−0.0600.2908−0.0760.1822−0.0390.4920−0.0640.2635DMARD (other than MTX) use^a^−0.0270.6361−0.0220.7002−0.0070.90180.0270.6386Duration of MTX use0.1000.08090.1090.05580.0630.26900.0710.2141MTX dose−0.0430.4554−0.0740.1946−0.0530.3550−0.0410.4730Comorbidity^a^0.0630.26800.0640.26260.1180.03840.0990.0823DAS28-CRP−0.1280.0246−0.1160.0430−0.1250.0290−0.0730.2002Total modified Sharp score−0.0490.39450.0690.22710.0590.30640.0600.2979HAQ−0.1040.0699−0.0350.5398−0.0600.2994−0.0480.4027MMP-3−0.1070.0608−0.1460.0103−0.1030.0726−0.1010.0783IL-6−0.1140.0461−0.0850.1357−0.0250.66390.0000.9948TNF−0.1500.0083−0.1630.0041−0.1690.0031−0.1580.0054RF−0.1920.0007−0.1880.0009−0.2010.0004−0.222\< 0.0001Anti-CCP−0.1530.0071−0.1210.0344−0.1330.0195−0.1720.0025*Abbreviations: BMI* Body mass index, *CCP* Cyclic citrullinated peptide antibodies, *DAS28-CRP* Disease Activity Score in 28 joints based on C-reactive protein, *HAQ* Health Assessment Questionnaire, *IL-6* Interleukin-6, *MMP-3* Matrix metalloproteinase-3, *MTX* Methotrexate, NSAID Nonsteroidal anti-inflammatory drug, *RF* Rheumatoid factor, *Rho* Spearman's rank correlation coefficient, *TNF* Tumor necrosis factor^a^Categories of response are 0 = no, 1 = yes

Correlation of patient baseline characteristics with the three classes stratified by baseline RF and anti-CCP titers {#Sec11}
--------------------------------------------------------------------------------------------------------------------

We initially hypothesized that TNF level should be low in patients who are negative for RF and anti-CCP at baseline, which would lead to high IFX levels. However, the relatively small patient group of 41 RF-negative patients and 25 anti-CCP-negative patients in the RISING study prevented analysis of differences in IFX level and disease activity at W54 between the three IFX dosing groups. To resolve this issue, we stratified the patients in the RISING study into three classes using cutoff values for both RF and anti-CCP as described in the Methods section above as low/low-C (RF-low/anti-CCP-low), high/high-C (RF-high/anti-CCP-high), and middle-C (those who did not meet the criteria for either class) (Additional file [2](#MOESM2){ref-type="media"}).

Table [4](#Tab4){ref-type="table"} shows patient baseline characteristics in the three stratified classes. A significant difference was observed in baseline TNF levels among three classes, with the TNF level being lowest in low/low-C (median 0.73 pg/ml), middle in middle-C (median 0.91 pg/ml), and highest in high/high-C (median 1.15 pg/ml). The proportions of patients with a high baseline TNF level ≥ 1.65 pg/ml \[[@CR18]\] in low/low-C, middle-C, and high/high-C were 8%, 8%, and 30%, respectively. Regarding disease activity and Health Assessment Questionnaire at baseline, significant differences were observed among the three classes; however, the values were lower in middle-C.Table 4Patient characteristics of the three classes stratified by rheumatoid factor and anti-cyclic citrullinated peptide antibodiesLow/low class (*n* = 53)Middle class (*n* = 183)High/high class (*n* = 71)*p* ValueRF, IU/ml11 (5, 30)87 (50, 139)384 (248, 604)\< 0.0001Anti-CCP, U/ml7 (2, 22)≥ 100 (38, ≥ 100)≥ 100 (≥ 100, ≥ 100)\< 0.0001Female sex89%83%76%0.1766^a^Age, years46.4 (13.0)49.3 (12.1)53.0 (10.3)0.0093BMI22.2 (4.2)22.0 (3.3)22.8 (3.9)0.3774Disease duration7.3 (6.9)7.9 (7.2)8.6 (8.7)0.8541NSAID use89%87%90%0.8299^a^Glucocorticoid use66%70%65%0.6263^a^DMARD (other than MTX) use32%31%31%0.9793^a^MTX dose, mg/week7.6 (1.7)7.9 (1.8)7.7 (1.7)0.5264Duration of MTX use2.7 (2.6)2.7 (2.8)2.6 (2.8)0.9885Comorbidity77%74%87%0.0810^a^DAS28-CRP5.54 (4.92, 6.42)5.39 (4.89, 6.01)5.74 (5.12, 6.37)0.0251Total modified Sharp score36.0 (8.0, 56.8)36.5 (12.0, 74.1)31.5 (13.0, 57.0)0.4305HAQ1.21 (0.68)1.11 (0.63)1.38 (0.67)0.0132MMP-3, ng/ml262 (132, 561)207 (105, 420)196 (101, 352)0.2372IL-6, pg/ml26.5 (12.3, 56.5)28.5 (12.4, 70.2)33.6 (15.1, 61.8)0.6163TNF, pg/ml0.73 (\< 0.55, 1.09)0.91 (\< 0.55, 1.23)1.15 (0.72, 1.82)0.0002 Low/intermediate/high^b^38%/55%/8%29%/63%/8%20%/51%/30%0.0007*Abbreviations: BMI* Body mass index, *CCP* Cyclic citrullinated peptide antibodies, *DAS28-CRP* Disease Activity Score in 28 joints based on C-reactive protein, *HAQ* Health Assessment Questionnaire, *IL-6* Interleukin-6, *MMP-3* Matrix metalloproteinase-3, *MTX* Methotrexate, NSAID Nonsteroidal anti-inflammatory drug, *RF* Rheumatoid factor, *Rho* Spearman's rank correlation coefficient, *TNF* Tumor necrosis factorData are mean (SD), median (interquartile range), or patients rate (%). The Kruskal-Wallis test was used to evaluate the differences among three classes unless otherwise noted^a^Chi-square test was used to evaluate the differences among three classes^b^Distribution of TNF levels were defined as follows: low \< 0.55, intermediate ≥ 0.55 to \< 1.65, and high ≥ 1.65 pg/ml \[[@CR18]\]

Correlation of serum IFX levels and disease activity until week 14 in the three stratified classes {#Sec12}
--------------------------------------------------------------------------------------------------

Table [5](#Tab5){ref-type="table"} shows the IFX levels in W2 to W14 and disease activity in W0 to W14 in the three classes. Significant differences in IFX levels were observed in W2 to W14, with observed levels highest in low/low-C and lowest in high/high-C. Even in high/high-C, median IFX levels in W2 to W10 (2 or 4 weeks after the previous infusion) were above the threshold level for clinical response (≥ 1.0 μg/ml), the value for which has been reported in previous clinical studies using the same ELISA system \[[@CR17], [@CR24], [@CR25]\]. However, in high/high-C, the median IFX level at W14 was 0.4 μg/ml, and the proportion of patients with IFX levels ≥ 1.0 μg/ml was only 30%. The corresponding proportion in middle-C was between that in low/low-C and that in high/high-C for each time point.Table 5Serum infliximab level and disease activity in three classes stratified on the basis of rheumatoid factor and anti-cyclic citrullinated peptide antibodiesLow/low class (*n* = 53)Middle class (*n* = 183)High/high class (*n* = 71)*p* ValueSerum infliximab level, μg/ml Week 213.9 (12.0, 15.7)13.2 (10.2, 16.3)12.0 (9.5, 14.2)0.0028 Week 67.6 (4.5, 10.8)7.1 (2.5, 10.0)5.0 (1.6, 8.2)0.0072 Week 107.7 (3.9, 10.5)6.3 (2.0, 10.3)3.8 (1.5, 7.9)0.0040 Week 141.5 (0.6, 2.1)0.7 (\<0.1, 2.0)0.4 (\<0.1, 1.1)0.0014 Week 14, \< 0.1/≥ 0.1 to \< 0.1/≥ 1.013%/25%/62%33%/25%/42%32%/38%/30%0.0015DAS28-CRP Week 23.89 (3.09, 4.51)3.90 (3.24, 4.52)4.01 (3.34, 4.79)0.2770 Week 63.32 (2.78, 4.16)3.42 (2.67, 4.22)3.68 (2.96, 4.36)0.2381 Week 103.19 (2.57, 3.77)3.24 (2.55, 4.12)3.48 (2.67, 4.20)0.3612 Week 143.17 (2.49, 3.69)3.53 (2.63, 4.36)3.82 (2.62, 4.97)0.0764 Week 14, REM/LDA/MDA/HDA17%/15%/51%/17%15%/12%/40%/33%18%/10%/31%/41%0.1455*Abbreviations: DAS28-CRP* Disease Activity Score in 28 joints based on C-reactive protein, *HDA* High disease activity, *LDA* Low disease activity without clinical remission, *MDA* Moderate disease activity, *REM* Clinical remissionData are median (interquartile range) or number of patients (%). Cutoff values for DAS28-CRP were as follows: REM \< 2.3, LDA ≥ 2.3 to \< 2.7, MDA ≥ 2.7 to ≤ 4.1, HDA \> 4.1 \[[@CR22]\]. The Kruskal-Wallis test was used to evaluate the differences among three classes

With regard to disease activity, an opposite trend was observed: The median DAS28-CRP was lowest in low/low-C and highest in high/high-C, although the difference (marginally significant) was observed only at W14 (8 weeks after the previous infusion).

Correlation of serum IFX levels and disease activity at week 54 with the three stratified classes in each IFX dosing group {#Sec13}
--------------------------------------------------------------------------------------------------------------------------

Figure [1a and b](#Fig1){ref-type="fig"} shows the IFX levels and DAS28-CRP at W54 in the three stratified classes in each IFX dosing group (3, 6, or 10 mg/kg group). In the 3 mg/kg dosing group, a significant difference in IFX levels at W54 was observed among the three stratified classes. The proportion of patients with IFX level ≥ 1.0 μg/ml at W54 was 52% in low/low-C but only 12% in high/high-C with a median IFX level of 0.1 μg/ml (close to the lower detection limit).Fig. 1**a**, **b** Serum infliximab level and disease activity at week 54 in three stratified classes. Differences among three classes stratified on the basis of rheumatoid factor and anti-cyclic citrullinated peptide antibodies at week 0 in serum infliximab (IFX) level at week 54 (**a**) and with disease activity at week 54 **b** were evaluated by Kruskal-Wallis test. Disease activity was evaluated using Disease Activity Score in 28 joints based on C-reactive protein with the following REM cutoff levels: \< 2.3, LDA ≥ 2.3 but \< 2.7, MDA ≥ 2.7 but ≤ 4.1, and HDA \> 4.1 \[[@CR22]\]. *HDA* High disease activity, *LDA* Low disease activity without clinical remission, *MDA* Moderate disease activity, *REM* Clinical remission

A significant difference was also observed in disease activity at W54 in patients receiving 3 mg/kg of IFX. The proportions of patients with REM and HDA were 48% and 9% in low/low-C and 24% and 38% in high/high-C, respectively. In patients receiving IFX at 6 or 10 mg/kg, the IFX level at W54 was lowest in high/high-C, but not to a significant degree. The median IFX level in high/high-C at W54 was 3.0 or 3.8 μg/ml in patients receiving 6 or 10 mg/kg of IFX, respectively, either of which was ≥ 1.0 μg/ml. With regard to disease activity at W54 in patients receiving IFX at 6 or 10 mg/kg, no significant difference was observed among the three classes. In addition, the proportion of patients with RF-high/anti-CCP-high decreased, and the proportion of those with RF-low/anti-CCP-low increased during IFX treatment in each dosing group, despite no differences among the three dosing groups (Additional file [3](#MOESM3){ref-type="media"}).

ATI positivity {#Sec14}
--------------

As described in the Methods section above, patients with detectable serum IFX levels (≥ 0.1 μg/ml) were defined as ATI-negative and were not evaluated for ATI positivity. ATI positivity was evaluated in 98 patients. ATI positivity rates in low/low-C, middle-C, and high/high-C were 13% (3 of 23, ATI was analyzed in 5), 34% (16 of 47, ATI was analyzed in 26), and 28% (8 of 29, ATI was analyzed in 14), respectively, in the 3 mg/kg dosing group (*n* = 99); 15% (3 of 20, ATI was analyzed in 6), 24% (15 of 62, ATI was analyzed in 21), and 27% (6 of 22, ATI was analyzed in 7), respectively, in the 6 mg/kg group (*n* = 104); and 10% (1 of 10, ATI was analyzed in 1), 14% (10 of 74, ATI was analyzed in 14), and 10% (2 of 20, ATI was analyzed in 4), respectively, in the 10 mg/kg group (*n* = 104). ATI positivity rates in low/low-C tended to be lower than in the other classes, but no significant difference was observed among the three dosing groups.

Discussion {#Sec15}
==========

Despite its efficacy in treating RA \[[@CR26]--[@CR29]\], IFX treatment is very costly. Therefore, predicting the clinical efficacy of IFX therapy is extremely important with regard to medical economics. Although prediction of the clinical efficacy of IFX therapy has been investigated in many studies, results have been controversial \[[@CR10], [@CR11], [@CR30]\]. Although researchers in some studies reported that early response predicted long-term responses \[[@CR31], [@CR32]\], identifying predictive factors "at baseline" would be even more worthwhile in establishing IFX treatment strategies.

Our previous findings derived from a post hoc analysis of the RISING study demonstrated that patients with a high baseline TNF level had low IFX levels during IFX therapy and that this was associated with a poor clinical response 1 year later, particularly in patients on 3 mg/kg therapy \[[@CR18]\]. However, TNF levels are generally quite low, and measurement results can differ markedly depending on the assay system used \[[@CR18], [@CR33]--[@CR35]\]. In addition, measurement of TNF levels is not routine in clinical practice. Thus, other factors that can easily be measured in the clinical setting and can predict the efficacy of IFX therapy are desired.

In this post hoc analysis of the RISING study, we found a positive correlation of baseline TNF level, and a negative correlation of IFX levels, in W2 to W14 with baseline RF and anti-CCP titers. We then stratified patients using baseline RF and anti-CCP titers into low/low-C, middle-C, and high/high-C to evaluate the correlation with TNF levels as well as IFX levels and clinical responses. We found that RF-high/anti-CCP-high patients (high/high-C) had higher baseline TNF and lower IFX levels than other classes (Tables [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"}).

In RF-high/anti-CCP-high patients, humoral immunity may be enhanced, leading to an increasing risk of ATI expression, which correlates with lower IFX levels \[[@CR36], [@CR37]\]. Indeed, ATI positivity was higher in high/high-C than in low/low-C in the 3 and 6 mg/kg dosing groups, despite the absence of a significant difference. Therefore, the low IFX level in high/high-C might be due to the induction of ATI production in this patient class. Meanwhile, we observed a negative correlation between baseline RF/anti-CCP and IFX level even at the early induction phase (W2, after the first infusion), in which most patients were thought not to produce ATI (Table [5](#Tab5){ref-type="table"}). We therefore considered that the correlation of baseline RF/anti-CCP with IFX level is likely due to the high baseline TNF level and that high ATI positivity in high/high-C may be the consequence of a low IFX level. However, we did not evaluate ATI positivity in patients with a detectable serum IFX level, and we did not exclude the effect of ATI production on the low IFX level.

Upon evaluating the correlation between DAS28-CRP until W14 and the three stratified classes, a significant correlation was observed in only at W14 (8 weeks after the previous infusion) (Table [5](#Tab5){ref-type="table"}). Although IFX levels at W2 to W10 were lower in high/high-C than in the other classes, ≥ 60% of patients in high/high-C had a serum level \> 1.0 μg/ml, which was reported as the threshold value for clinical response in several clinical studies using the same ELISA system \[[@CR17], [@CR24], [@CR25]\]. In contrast, the median serum IFX level at W14 was 0.4 μg/ml, and approximately one-third of patients showed a level that was below the lower limit of detection (\< 0.1 μg/ml). Given these findings, we believe that the difference (marginally significant) in disease activity observed only at W14 was likely due to the markedly low IFX levels at W14 in high/high-C.

Similarly to these findings at W14, significant differences in IFX levels and disease activity were also observed at W54 in patients who continued to receive IFX at 3 mg/kg (Fig. [1a and b](#Fig1){ref-type="fig"}): high IFX levels and LDA in low/low-C, low IFX levels and HDA in high/high-C, and intermediate values in middle-C. Given these findings, baseline RF and anti-CCP titers were clearly associated with treatment response at W54 in patients receiving 3 mg/kg IFX.

In contrast, in patients receiving IFX at 6 or 10 mg/kg, IFX level at W54 tended to be lowest in high/high-C. However, no significant difference was observed in either IFX level or disease activity. In high/high-C, the median IFX levels at W54 in the 6 and 10 mg/kg dosing groups were 3.0 and 3.8 μg/ml, respectively, and the proportions of patients with a level above the threshold for clinical response (≥ 1.0 μg/ml) at W54 were 60% and 80%, respectively. Given these findings, the lack of difference in disease activity at W54 in the 6 and 10 mg/kg dosing groups was likely due to the sufficiently high IFX levels observed even in high/high-C.

Upon comparing disease activity criteria between the three IFX dosing groups (3, 6, and 10 mg/kg), in each of the three classes, no significant difference was observed in low/low-C (*p* = 0.845 by Kruskal-Wallis test), whereas some degree of difference was observed in high/high-C (*p =* 0.183) and middle-C (*p* = 0.026). These findings suggest that dose escalation of IFX might not be clinically meaningful in low/low-C, most of whom maintained the threshold for clinical response. Dose escalation would therefore be more effective in middle-C and high/high-C.

In addition to baseline RF and anti-CCP titers, sex was found to be significantly correlated with IFX levels in W2 to W14; indeed, IFX levels tended to be higher in female than in male patients. However, baseline RF titers were significantly lower in female patients, and baseline TNF levels tended to be lower in female than in male patients (median 0.90 versus 1.03 pg/ml). In addition, the female-to-male ratio in high/high-C was lower than in low/low-C (data not shown). Differences in baseline RF and TNF levels and in female-to-male ratio among the classes might have contributed to the apparent correlations between sex and IFX levels.

Although details regarding the mechanism underlying the correlation between RF/anti-CCP and TNF levels are unknown, a previous in vitro study showed that anti-CCP induced the production of inflammatory cytokines in the synovial membrane and that this was amplified by RF \[[@CR38]\]. This finding suggests that the induction of TNF production in the synovial membrane may elevate circulating TNF levels in patients with high RF/anti-CCP titers. In this study, RF and anti-CCP titers at W54 were significantly decreased in all three IFX dosing groups compared with those at W0 (Additional file [3](#MOESM3){ref-type="media"}), suggesting that a "vicious cycle" might exist in patients with RA whereby RF/anti-CCP promotes TNF production, which in turn contributes to further induction of RF/anti-CCP through an as yet unknown mechanism.

In the BeSt Study, patients who sustained drug-free remission were reported to have significantly lower baseline RF and anti-CCP titers than those who did not \[[@CR39]\]. In patients in whom RF and anti-CCP titers returned to the normal range with IFX therapy, the aforementioned "vicious cycle" might have been stopped. This stop might enable tapering of IFX in these patients with RA (i.e., dose reduction or withdrawal). However, further study is needed to prove this hypothesis.

Some IFX biosimilars, which are available for rheumatological as well as dermatological and gastroenterological conditions in some countries, have been reported to show the same efficacy, safety, and pharmacokinetics as the IFX originator Remicade \[[@CR40]\]. Therefore, our results might theoretically be applicable to these IFX biosimilars. However, we used only the IFX originator in this study, and further study is needed to confirm the adaptation.

Several limitations of this study warrant mention. The first and most critical limitation is that the upper detection limit for anti-CCP was 100 U/ml, and baseline anti-CCP titers were ≥ 100 U/ml in 58% of patients in this study. Because of this low upper limit, we could not stratify three classes using a "true second tertile" of anti-CCP (58% were stratified as anti-CCP-high), and analyses in patients with an extremely high anti-CCP titer were difficult. Second, we could not delineate each influence of RF or anti-CCP on TNF level, IFX levels, or disease activity, because RF and anti-CCP were significantly correlated (rho = 0.373, *p* \< 0.0001) and resulted in the small numbers of patients with RF-high/anti-CCP-low or RF-low/anti-CCP-high. Third, TNF level could not be explained solely using RF and anti-CCP titers. Despite the significant correlation of RF/anti-CCP titers with TNF level, the correlation coefficients were low. In addition, TNF level was also significantly correlated with other baseline characteristics, such as DAS28-CRP, age, and IL-6 level. Accordingly, we cannot rule out the possibility that other factors besides RF/anti-CCP titers influenced the TNF level. Fourth, IFX levels may not actually be linked to baseline RF/anti-CCP titers, but may be linked to RF/anti-CCP titers at the point of measurement. Although both RF and anti-CCP titers were significantly reduced in all three dosing groups after IFX treatment (Additional file [3](#MOESM3){ref-type="media"}), both autoantibody levels at baseline and W54 were closely correlated in this study (rho = 0.819 for RF, rho = 0.871 for anti-CCP). In addition, IFX levels at W54 tended to be more strongly correlated with RF and anti-CCP titers at W54 than at W0 (data not shown). Under these conditions, some inaccuracy may exist when predicting clinical response on the basis of baseline RF/anti-CCP titers in certain patient populations, such as those showing extreme or no change of RF/anti-CCP titers regardless of their clinical response during IFX therapy. Allowing for these limitations, these findings will provide useful indices for IFX treatment strategy. However, given that the RISING study did not measure circulating autoantibodies other than RF and anti-CCP, future studies may be required to clarify the influence of other autoantibodies on IFX levels and clinical responses in patients with RA.

Conclusions {#Sec16}
===========

The findings of our present post hoc analysis of the RISING study demonstrated that baseline RF and anti-CCP titers are associated with both TNF level at baseline and IFX levels during subsequent IFX therapy, as well as that clinical responses are predictable to some degree before the start of IFX therapy. These findings will provide useful indices in implementing a strategy for long-term use of IFX in accordance with treat-to-target strategy \[[@CR41], [@CR42]\].
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